NASDAQ:CCXI - ChemoCentryx Stock Price, Price Target & More

$10.82 -0.09 (-0.82 %)
(As of 04/23/2018 01:46 AM ET)
Previous Close$10.82
Today's Range$10.68 - $10.97
52-Week Range$5.42 - $15.08
Volume103,025 shs
Average Volume192,756 shs
Market Capitalization$530.95 million
P/E Ratio30.06
Dividend YieldN/A
Beta1.58

About ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx logoChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Debt-to-Equity Ratio0.06%
Current Ratio5.46%
Quick Ratio5.46%

Price-To-Earnings

Trailing P/E Ratio30.06
Forward P/E Ratio-9.17
P/E GrowthN/A

Sales & Book Value

Annual Sales$82.50 million
Price / Sales6.44
Cash Flow$0.3747 per share
Price / Cash28.88
Book Value$1.63 per share
Price / Book6.64

Profitability

EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net MarginsN/A
Return on Equity35.06%
Return on Assets11.71%

Miscellaneous

Employees66
Outstanding Shares49,070,000

How to Become a New Pot Stock Millionaire

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx (NASDAQ:CCXI) posted its quarterly earnings results on Friday, March, 9th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the consensus estimate of ($0.22) by $1.02. The biopharmaceutical company had revenue of $56.30 million for the quarter, compared to analysts' expectations of $9.03 million. View ChemoCentryx's Earnings History.

What price target have analysts set for CCXI?

2 analysts have issued twelve-month price targets for ChemoCentryx's stock. Their forecasts range from $16.00 to $16.00. On average, they expect ChemoCentryx's share price to reach $16.00 in the next twelve months. View Analyst Ratings for ChemoCentryx.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:
  • 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (3/15/2018)
  • 2. Cowen Inc analysts commented, "ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30." (8/8/2017)

Who are some of ChemoCentryx's key competitors?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:
  • Dr. Thomas J. Schall, Founder, Chairman, CEO & Pres (Age 59)
  • Ms. Susan M. Kanaya, Chief Financial & Admin. Officer, Exec. VP and Sec. (Age 55)
  • Mr. William Fairey, Exec. VP & COO
  • Dr. Markus J. Cappel Ph.D., Chief Bus. Officer and Treasurer (Age 57)
  • Dr. Rajinder Singh Ph.D., Sr. VP of Research (Age 51)

Has ChemoCentryx been receiving favorable news coverage?

Media coverage about CCXI stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ChemoCentryx earned a coverage optimism score of 0.05 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.85 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $10.82.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $530.95 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]


MarketBeat Community Rating for ChemoCentryx (CCXI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ChemoCentryx (NASDAQ:CCXI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for ChemoCentryx in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 47.87%. The high price target for CCXI is $16.00 and the low price target for CCXI is $16.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00N/AN/A
Price Target Upside: 47.87% upside22.89% upsideN/AN/A

ChemoCentryx (NASDAQ:CCXI) Consensus Price Target History

Price Target History for ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx (NASDAQ:CCXI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2018JPMorgan ChaseReiterated RatingOverweight -> Overweight$13.00 -> $16.00MediumView Rating Details
8/8/2017CowenReiterated RatingHoldHighView Rating Details
2/21/2017JMP SecuritiesInitiated CoverageMkt Outperform -> OutperformN/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

ChemoCentryx (NASDAQ:CCXI) Earnings History and Estimates Chart

Earnings by Quarter for ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx (NASDAQ:CCXI) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS

ChemoCentryx (NASDAQ CCXI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2018Q4 2017($0.22)$0.80$9.03 million$56.30 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.26)($0.13)$8.94 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.17)($0.19)$8.94 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.2550)($0.12)$8.23 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.22)($0.16)$4.89 millionViewN/AView Earnings Details
11/7/2016Q3($0.08)($0.15)ViewListenView Earnings Details
8/8/2016Q2 2016$0.07($0.22)$2.80 millionViewN/AView Earnings Details
5/10/2016Q1($0.27)($0.34)ViewListenView Earnings Details
3/14/2016Q4($0.28)($0.26)ViewN/AView Earnings Details
11/9/2015Q315($0.29)($0.26)ViewListenView Earnings Details
8/6/2015Q215($0.29)($0.28)ViewN/AView Earnings Details
5/6/2015Q115($0.28)($0.28)ViewListenView Earnings Details
3/12/2015Q414($0.28)($0.28)ViewListenView Earnings Details
11/5/2014Q3 2014($0.29)($0.25)ViewN/AView Earnings Details
8/5/2014Q2 2014($0.27)($0.28)ViewN/AView Earnings Details
5/8/2014Q114($0.24)($0.27)$0.38 millionViewN/AView Earnings Details
3/13/2014($0.25)($0.22)$1.37 million$0.73 millionViewN/AView Earnings Details
11/7/2013Q3 2013($0.26)($0.22)$1.97 million$1.52 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.28)($0.23)$1.48 million$1.90 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.27)($0.28)$2.04 million$1.90 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.29)($0.28)ViewN/AView Earnings Details
11/13/2012Q312($0.28)$1.44 million$1.13 millionViewN/AView Earnings Details
8/10/2012Q2 2012($0.19)($0.30)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.20)($0.28)ViewN/AView Earnings Details
3/30/2012Q4 2011$0.44$0.61ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ChemoCentryx (NASDAQ:CCXI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ChemoCentryx (NASDAQ CCXI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 48.24%
Insider Trading History for ChemoCentryx (NASDAQ:CCXI)
Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx (NASDAQ CCXI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2017Roger C LucasDirectorSell2,250$10.07$22,657.5093,846View SEC Filing  
7/13/2017Petrus BekkerInsiderSell76,013$9.95$756,329.3565,963View SEC Filing  
7/12/2017Petrus BekkerInsiderSell30,000$9.98$299,400.0065,963View SEC Filing  
7/11/2017Petrus BekkerInsiderSell30,000$9.78$293,400.0065,963View SEC Filing  
7/10/2017Petrus BekkerInsiderSell19,877$9.30$184,856.1079,426View SEC Filing  
6/30/2017Petrus BekkerInsiderSell65,509$9.17$600,717.5389,839View SEC Filing  
5/1/2017Roger C LucasDirectorSell4,000$7.31$29,240.0062,822View SEC Filing  
1/3/2017Markus J CappelInsiderSell26,821$7.51$201,425.7120,833View SEC Filing  
12/16/2016Petrus BekkerInsiderSell8,712$8.74$76,142.8855,638View SEC Filing  
12/5/2016Petrus BekkerInsiderSell30,000$8.50$255,000.0083,594View SEC Filing  
11/22/2016Petrus BekkerInsiderSell1,250$8.30$10,375.0054,844View SEC Filing  
11/11/2016Petrus BekkerInsiderSell33,332$8.00$266,656.0054,228View SEC Filing  
9/1/2016Roger C LucasDirectorSell4,000$5.07$20,280.0074,822View SEC Filing  
5/23/2016James L TyreeDirectorSell5,544$4.39$24,338.1626,119View SEC Filing  
5/17/2016Thomas A EdwardsDirectorBuy50,000$4.05$202,500.0091,977View SEC Filing  
5/16/2016Thomas A EdwardsDirectorBuy25,000$4.05$101,250.0041,977View SEC Filing  
5/13/2016Geoffrey M ParkerDirectorBuy40,000$4.03$161,200.0013,514View SEC Filing  
1/22/2016Susan M. KanayaCFOSell25,764$4.04$104,086.56View SEC Filing  
1/20/2016Susan M. KanayaCFOSell14,971$4.10$61,381.10View SEC Filing  
1/19/2016Susan M. KanayaCFOSell6,134$4.05$24,842.70View SEC Filing  
1/15/2016Susan M. KanayaCFOSell300$4.00$1,200.00View SEC Filing  
1/11/2016Geoffrey M ParkerDirectorBuy20,000$4.63$92,600.0013,514View SEC Filing  
1/8/2016Susan M. KanayaCFOSell10,224$5.12$52,346.88View SEC Filing  
1/6/2016Susan M. KanayaCFOSell47,607$6.98$332,296.86View SEC Filing  
1/5/2016Susan M. KanayaCFOSell34,341$6.90$236,952.90View SEC Filing  
1/4/2016Susan M. KanayaCFOSell10,490$7.38$77,416.20View SEC Filing  
12/11/2015Geoffrey M ParkerDirectorBuy20,000$7.25$145,000.0013,514View SEC Filing  
11/4/2015Value Fund L P BiotechnologyInsiderSell360,000$7.00$2,520,000.00View SEC Filing  
11/2/2015Value Fund L P BiotechnologyInsiderSell50,000$6.97$348,500.00View SEC Filing  
6/10/2015Bvf Partners L P/IlMajor ShareholderSell955,700$9.00$8,601,300.00View SEC Filing  
5/22/2015Ira KleinDirectorSell10,811$7.44$80,433.84View SEC Filing  
4/1/2015Thomas J SchallCEOSell24,267$7.50$182,002.50View SEC Filing  
3/31/2015Thomas J SchallCEOSell16,540$7.55$124,877.00View SEC Filing  
3/30/2015Thomas J SchallCEOSell1,200$7.51$9,012.00View SEC Filing  
3/24/2015Thomas J SchallCEOSell50,371$7.84$394,908.64View SEC Filing  
3/19/2015Thomas J SchallCEOSell18,146$8.34$151,337.64View SEC Filing  
3/17/2015Thomas J SchallCEOSell31,316$8.55$267,751.80View SEC Filing  
3/9/2015Markus J CappelTreasurerSell34,125$7.81$266,516.25View SEC Filing  
3/4/2015Markus J CappelTreasurerSell40,875$7.98$326,182.50View SEC Filing  
3/3/2015Markus J CappelTreasurerSell5,943$7.81$46,414.83View SEC Filing  
3/2/2015Markus J CappelTreasurerSell14,390$8.13$116,990.70View SEC Filing  
11/18/2014Anne-Marie DuliegeEVPSell4,970$4.71$23,408.70View SEC Filing  
5/1/2014Thomas J SchallCEOSell27,726$5.59$154,988.34View SEC Filing  
4/29/2014Thomas J SchallCEOSell32,274$5.38$173,634.12View SEC Filing  
4/22/2014Markus J CappelTreasurerSell20,962$8.17$171,259.54View SEC Filing  
3/17/2014Thomas J SchallCEOSell20,000$7.25$145,000.00View SEC Filing  
12/6/2013Geoffrey M ParkerDirectorBuy20,000$5.15$103,000.00View SEC Filing  
12/5/2013Bvf Partners L P/IlMajor ShareholderBuy189,800$5.01$950,898.00View SEC Filing  
11/6/2013Bvf Partners L P/IlMajor ShareholderBuy136,066$4.92$669,444.72View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy336,225$4.99$1,677,762.75View SEC Filing  
10/9/2013Bvf Partners L P/IlMajor ShareholderBuy1,289,354$5.34$6,885,150.36View SEC Filing  
10/3/2013Bvf Partners L P/IlMajor ShareholderBuy109,425$5.49$600,743.25View SEC Filing  
9/13/2013Bvf Partners L P/IlMajor ShareholderBuy325,635$5.95$1,937,528.25View SEC Filing  
9/13/2013Joseph M FeczkoDirectorBuy10,000$6.03$60,300.00View SEC Filing  
8/13/2013Markus J CappelTreasurerSell5,459$12.90$70,421.10View SEC Filing  
8/7/2013Petrus BekkerSVPSell5,000$13.26$66,300.00View SEC Filing  
8/5/2013Roger C LucasDirectorSell5,000$13.42$67,100.00View SEC Filing  
8/1/2013Markus J CappelTreasurerSell6,250$13.82$86,375.00View SEC Filing  
7/17/2013Markus J CappelTreasurerSell5,459$14.52$79,264.68View SEC Filing  
7/17/2013Petrus BekkerSVPSell10,000$14.54$145,400.00View SEC Filing  
7/16/2013Thomas J SchallCEOSell22,089$14.39$317,860.71View SEC Filing  
7/3/2013Roger C LucasDirectorSell5,000$13.43$67,150.00View SEC Filing  
7/2/2013Markus J CappelTreasurerSell6,250$13.88$86,750.00View SEC Filing  
6/28/2013Susan M KanayaCFOSell36,942$14.31$528,640.02View SEC Filing  
6/27/2013Petrus BekkerSVPSell5,000$14.00$70,000.00View SEC Filing  
6/21/2013Markus J CappelTreasurerSell6,250$13.00$81,250.00View SEC Filing  
6/18/2013Markus J CappelTreasurerSell1,783$12.47$22,234.01View SEC Filing  
6/17/2013Petrus BekkerSVPSell5,000$12.00$60,000.00View SEC Filing  
6/3/2013Roger C LucasDirectorSell5,000$13.32$66,600.00View SEC Filing  
5/30/2013Susan M KanayaCFOSell12,770$14.28$182,355.60View SEC Filing  
5/28/2013Markus J CappelTreasurerSell3,676$14.10$51,831.60View SEC Filing  
5/24/2013Petrus BekkerSVPSell4,800$14.00$67,200.00View SEC Filing  
5/17/2013Petrus BekkerSVPSell15,000$13.97$209,550.00View SEC Filing  
5/15/2013Markus J CappelTreasurerSell15,668$14.08$220,605.44View SEC Filing  
5/15/2013Roger C LucasDirectorSell5,000$14.11$70,550.00View SEC Filing  
5/15/2013Thomas J SchallCEOSell7,600$14.04$106,704.00View SEC Filing  
4/11/2013Markus J CappelTreasurerSell1,500$14.10$21,150.00View SEC Filing  
4/11/2013Petrus BekkerSVPSell3,979$14.03$55,825.37View SEC Filing  
4/11/2013Thomas J SchallCEOSell2,529$14.02$35,456.58View SEC Filing  
3/6/2013Petrus BekkerSVPSell11,502$13.98$160,797.96View SEC Filing  
3/6/2013Thomas J SchallCEOSell5,541$14.01$77,629.41View SEC Filing  
3/4/2013Roger C LucasDirectorSell5,000$13.87$69,350.00View SEC Filing  
2/26/2013Juan C JaenSVPSell22,500$12.23$275,175.00View SEC Filing  
2/22/2013Thomas J SchallCEOSell7,500$12.06$90,450.00View SEC Filing  
2/6/2013Roger C LucasDirectorSell3,857$11.52$44,432.64View SEC Filing  
2/4/2013Juan C JaenSVPSell3,875$11.69$45,298.75View SEC Filing  
1/17/2013Markus J CappelTreasurerSell2,700$11.16$30,132.00View SEC Filing  
11/6/2012Bvf Partners L P/IlMajor ShareholderBuy40,000$12.00$480,000.00View SEC Filing  
10/4/2012Roger C LucasDirectorSell1,893$11.47$21,712.71View SEC Filing  
10/1/2012Susan M KanayaCFOSell3,971$11.89$47,215.19View SEC Filing  
10/1/2012Thomas J SchallCEOSell15,000$11.53$172,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ChemoCentryx (NASDAQ CCXI) News Headlines

Source:
DateHeadline
Free Research Report as ChemoCentryx’s Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-YFree Research Report as ChemoCentryx’s Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y
finance.yahoo.com - April 19 at 8:12 AM
ChemoCentryx (CCXI) Upgraded at TheStreetChemoCentryx (CCXI) Upgraded at TheStreet
www.americanbankingnews.com - April 18 at 10:41 AM
ChemoCentryx (CCXI) Receives Consensus Recommendation of "Hold" from BrokeragesChemoCentryx (CCXI) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 9:56 AM
ChemoCentryx (CCXI) Downgraded to Hold at ValuEngineChemoCentryx (CCXI) Downgraded to Hold at ValuEngine
www.americanbankingnews.com - April 17 at 11:37 AM
Zacks: ChemoCentryx (CCXI) Given Consensus Rating of "Buy" by AnalystsZacks: ChemoCentryx (CCXI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 16 at 5:19 PM
ChemoCentryx (CCXI) Expected to Post Earnings of -$0.29 Per ShareChemoCentryx (CCXI) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 14 at 7:41 AM
ChemoCentryx (CCXI) Stock Rating Lowered by BidaskClubChemoCentryx (CCXI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM
Should You Be Tempted To Sell ChemoCentryx Inc (NASDAQ:CCXI) At Its Current PE Ratio?Should You Be Tempted To Sell ChemoCentryx Inc (NASDAQ:CCXI) At Its Current PE Ratio?
finance.yahoo.com - April 13 at 8:16 AM
ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical MeetingChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
finance.yahoo.com - April 11 at 5:35 PM
Recent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Ericsson, Toronto Dominion Bank, Odonate Therapeutics, Colliers International Group, ChemoCentryx, and CyberArk Software Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 10 at 8:20 AM
Can ChemoCentryx Inc (NASDAQ:CCXI) Continue To Outperform Its Industry?Can ChemoCentryx Inc (NASDAQ:CCXI) Continue To Outperform Its Industry?
finance.yahoo.com - April 4 at 4:16 PM
Active-Investors: Wired News - Exelixis Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYXActive-Investors: Wired News - Exelixis' Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX
www.finanznachrichten.de - April 2 at 8:33 AM
Wired News – Exelixis’ Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYXWired News – Exelixis’ Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX
finance.yahoo.com - April 2 at 8:33 AM
ChemoCentryx Inc (CCXI) Expected to Post Earnings of -$0.29 Per ShareChemoCentryx Inc (CCXI) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - March 28 at 9:59 AM
ChemoCentryx: Significant Progress In Recent MonthsChemoCentryx: Significant Progress In Recent Months
seekingalpha.com - March 24 at 5:18 PM
ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 ...ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 ...
globenewswire.com - March 24 at 5:18 PM
ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
finance.yahoo.com - March 22 at 5:38 PM
Edited Transcript of CCXI earnings conference call or presentation 9-Mar-18 1:30pm GMTEdited Transcript of CCXI earnings conference call or presentation 9-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 8:14 AM
ChemoCentryx (CCXI) Rating Lowered to Hold at Zacks Investment ResearchChemoCentryx (CCXI) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 15 at 7:06 PM
ChemoCentryx (CCXI) Upgraded to Buy at ValuEngineChemoCentryx (CCXI) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - March 15 at 12:28 AM
ChemoCentryx (CCXI) Upgraded at BidaskClubChemoCentryx (CCXI) Upgraded at BidaskClub
www.americanbankingnews.com - March 14 at 7:51 PM
ChemoCentryx (CCXI) Stock Rating Upgraded by Zacks Investment ResearchChemoCentryx (CCXI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 14 at 7:17 PM
 ChemoCentryx Inc (CCXI) Given $13.00 Consensus Price Target by Analysts ChemoCentryx Inc (CCXI) Given $13.00 Consensus Price Target by Analysts
www.americanbankingnews.com - March 13 at 9:26 PM
ChemoCentryx (CCXI) PT Raised to $16.00 at JPMorgan Chase & Co.ChemoCentryx (CCXI) PT Raised to $16.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - March 13 at 3:55 PM
ChemoCentryx (CCXI) Q4 2017 Earnings Conference Call TranscriptChemoCentryx (CCXI) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 11 at 8:12 AM
ChemoCentryx (CCXI) Releases  Earnings Results, Beats Estimates By $1.02 EPSChemoCentryx (CCXI) Releases Earnings Results, Beats Estimates By $1.02 EPS
www.americanbankingnews.com - March 10 at 9:36 AM
ChemoCentryxs (CCXI) CEO Tom Schall on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaChemoCentryx's (CCXI) CEO Tom Schall on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 10 at 8:18 AM
ChemoCentryx Inc (NASDAQ:CCXI): When Will It Breakeven?ChemoCentryx Inc (NASDAQ:CCXI): When Will It Breakeven?
finance.yahoo.com - March 9 at 6:55 PM
ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent HighlightsChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 9 at 8:16 AM
Chemocentryx, Inc. to Host Earnings CallChemocentryx, Inc. to Host Earnings Call
finance.yahoo.com - March 9 at 8:16 AM
ChemoCentryx posts 4Q profitChemoCentryx posts 4Q profit
finance.yahoo.com - March 9 at 8:16 AM
ChemoCentryx beats by $1.00, beats on revenueChemoCentryx beats by $1.00, beats on revenue
seekingalpha.com - March 9 at 7:14 AM
Form 4 ChemoCentryx, Inc. For: Mar 05 Filed by: Schall Thomas J.Form 4 ChemoCentryx, Inc. For: Mar 05 Filed by: Schall Thomas J.
www.streetinsider.com - March 8 at 8:19 AM
ChemoCentryx to Present at the Cowen and Company 38th Annual Health Care ConferenceChemoCentryx to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 5:43 PM
ChemoCentryx (CCXI) Stock Rating Upgraded by BidaskClubChemoCentryx (CCXI) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 3 at 6:10 PM
ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018
finance.yahoo.com - March 1 at 5:54 PM
ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018
feeds.benzinga.com - March 1 at 8:46 AM
Zacks: ChemoCentryx Inc (CCXI) Receives Consensus Recommendation of "Buy" from AnalystsZacks: ChemoCentryx Inc (CCXI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 26 at 5:34 AM
Zacks: Analysts Set $13.00 Target Price for ChemoCentryx Inc (CCXI)Zacks: Analysts Set $13.00 Target Price for ChemoCentryx Inc (CCXI)
www.americanbankingnews.com - February 4 at 5:16 AM
ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic CancerChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer
finance.yahoo.com - January 23 at 5:28 PM
ChemoCentryx (CCXI) & Ocera Therapeutics (OCRX) Financial ReviewChemoCentryx (CCXI) & Ocera Therapeutics (OCRX) Financial Review
www.americanbankingnews.com - January 16 at 7:56 PM
Head to Head Review: Argos Therapeutics (ARGS) vs. ChemoCentryx (CCXI)Head to Head Review: Argos Therapeutics (ARGS) vs. ChemoCentryx (CCXI)
www.americanbankingnews.com - January 12 at 3:16 AM
 ChemoCentryx Inc (CCXI) Receives Consensus Recommendation of "Buy" from Analysts ChemoCentryx Inc (CCXI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 5 at 8:06 AM
Here's Why ChemoCentryx Rose as Much as 53.5% TodayHere's Why ChemoCentryx Rose as Much as 53.5% Today
finance.yahoo.com - January 4 at 5:33 PM
Heres Why ChemoCentryx Rose as Much as 53.5% TodayHere's Why ChemoCentryx Rose as Much as 53.5% Today
www.fool.com - January 4 at 2:11 PM
Vifor Pharma Ltd.: AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCYVifor Pharma Ltd.: AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY
www.finanznachrichten.de - January 4 at 9:15 AM
BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional ReviewBRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review
www.reuters.com - January 4 at 9:15 AM
ETFs with exposure to ChemoCentryx, Inc. : December 28, 2017ETFs with exposure to ChemoCentryx, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:35 PM
ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 5:06 PM
Should You Buy ChemoCentryx Inc (CCXI) Now?Should You Buy ChemoCentryx Inc (CCXI) Now?
finance.yahoo.com - November 27 at 6:20 PM

SEC Filings

ChemoCentryx (NASDAQ:CCXI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ChemoCentryx (NASDAQ:CCXI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ChemoCentryx (NASDAQ CCXI) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.